UCB (OTCMKTS:UCBJF) Sees Strong Trading Volume - Here's Why

Key Points

• UCB shares experienced a significant increase in trading volume, with 15,184 shares traded, marking a 1,519% rise compared to the previous day.
• Morgan Stanley has upgraded UCB shares to an "overweight" rating, indicating expected growth potential in the company's stock performance.
• The stock closed at $227.63 after previously closing at $222.29, reflecting a 2.4% increase in value.

Shares of UCB SA (OTCMKTS:UCBJF - Get Free Report) saw an uptick in trading volume on Friday . 15,184 shares were traded during trading, an increase of 1,519% from the previous session's volume of 938 shares.The stock last traded at $227.63 and had previously closed at $222.29.

Analyst Ratings Changes

Separately, Morgan Stanley raised shares of UCB to an "overweight" rating in a research report on Monday, June 23rd. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy".

UCB Trading Down 1.1%

The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The business's fifty day moving average is $207.18 and its 200 day moving average is $186.97.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.